Adipositas - Ursachen, Folgeerkrankungen, Therapie 2017; 11(02): 69-75
DOI: 10.1055/s-0037-1618960
Übersichtsarbeit
Schattauer GmbH

Summary of the “2016 European Guidelines on Cardiovascular Disease Prevention in Clinical Practice”

Article in several languages: deutsch | EnglishS. Engeli1
  • 1Institut für Klinische Pharmakologie, Medizinische Hochschule Hannover (Direktor: Dirk O. Stichtenoth)
Further Information

Publication History

Publication Date:
29 December 2017 (online)

Summary

Application of the “2016 European Guidelines on Cardiovascular Disease Prevention in Clinical Practice” allows a precise and individualized cardiovascular risk estimation that can easily be employed in clinical practice. Preventive and therapeutic measures based on quantitative risk assessments (e.g. blood pressure, blood lipids, HbA1c, duration and intensity of weekly exercise) are well defined and mostly based on solid evidence from randomized trials and meta-analyses. This is not the case for most recommendations dealing with so-called life-style changes and population-based activities. With the exception of measures against smoking that have been proven to be efficacious, most other recommendations are vaguely defined and especially on the population level, merely represent not well validated expert opinions. It is this particular spectrum of recommendations that needs intensified attention in the future to increase their validity.